BiolineRx Will Pay $15M As An Upfront Payment, And Granted Hong Seng Technology Can Receive Up To $49M Based On The Achievement Of Certain Development And Regulatory Milestones In China And Japan, And Up To $197M As Sales-Based Milestones
Portfolio Pulse from Benzinga Newsdesk
BiolineRx has agreed to pay $15M upfront to Hong Seng Technology, with the potential for Hong Seng to receive up to $49M based on the achievement of certain development and regulatory milestones in China and Japan, and up to $197M as sales-based milestones.
August 30, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The deal could potentially increase BiolineRx's expenses in the short term due to the upfront payment, but could also lead to long-term gains if Hong Seng Technology achieves the set milestones.
The upfront payment of $15M will increase BiolineRx's expenses in the short term. However, the potential for Hong Seng to receive additional payments based on the achievement of development and regulatory milestones, as well as sales-based milestones, could lead to increased revenues for BiolineRx in the long term if these milestones are achieved.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100